Top Page
Modalis Therapeutics Corporation
(4883)
Modalis Therapeutics Corporation (4883) vs. iShares MSCI Japan ETF (EWJ)
Modalis Therapeutics Corporation Business Overview & Revenue Model
Modalis Therapeutics Corporation Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 40.50M | 1.10M | 342.00M |
| Gross Profit | 0.00 | -731.00K | -83.17M | 1.10M | 342.00M |
| EBITDA | -2.15B | -2.37B | -2.58B | -667.55M | -381.96M |
| Net Income | -1.32B | -2.39B | -2.70B | -738.96M | -448.41M |
Balance Sheet | |||||
| Total Assets | 3.69B | 2.03B | 3.13B | 6.07B | 6.28B |
| Cash, Cash Equivalents and Short-Term Investments | 3.58B | 1.88B | 2.93B | 4.94B | 5.42B |
| Total Debt | 0.00 | 412.50M | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 143.47M | 645.50M | 188.60M | 519.92M | 70.16M |
| Stockholders Equity | 3.55B | 1.38B | 2.94B | 5.55B | 6.21B |
Cash Flow | |||||
| Free Cash Flow | -1.43B | -2.29B | -2.09B | -854.58M | -1.21B |
| Operating Cash Flow | -1.43B | -2.25B | -1.90B | -747.47M | -376.57M |
| Investing Cash Flow | -188.00K | -39.70M | -185.72M | 171.56M | -830.31M |
| Financing Cash Flow | 3.04B | 1.22B | 63.68M | 72.63M | 2.78B |
Modalis Therapeutics Corporation Technical Analysis
Modalis Therapeutics Corporation Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | ¥355.44B | 11.10 | -2.99% | 2.49% | 11.76% | -10.16% | |
55 Neutral | ¥13.82B | ― | ― | 109.03% | 98.53% | ||
55 Neutral | ¥13.08B | ― | ― | 57.13% | -66.39% | ||
48 Neutral | ¥10.00B | ― | ― | 14.41% | 27.42% | ||
48 Neutral | $166.15B | ― | -197.82% | ― | ― | -3.32% | |
40 Underperform | ¥9.75B | ― | -26.97% | ― | -30.46% | 39.41% | |
39 Underperform | ¥7.00B | ― | ― | ― | 59.56% |
Modalis Therapeutics Corporation Corporate Events
Modalis Therapeutics Corporation has completed the pay-in procedures for the issuance of 21,900 new common shares as part of a restricted-stock-based remuneration plan. This move, approved by the Board of Directors, aims to reward and incentivize directors, employees, and former employees, potentially enhancing stakeholder alignment and company performance.
Modalis Therapeutics Corporation announced the terms and conditions for its 16th stock option program, which includes issuing 8,800 share acquisition rights at an exercise price of 9,300 yen per unit. This move is aimed at incentivizing the company’s directors, employees, and subsidiary employees, potentially impacting the company’s market positioning and stakeholder engagement.
Modalis Therapeutics Corporation has announced the issuance of 21,900 new shares as part of a restricted-stock-based remuneration plan. This initiative is designed to incentivize directors and employees by aligning their interests with the company’s long-term goals. The issuance is part of a broader strategy to enhance corporate value and involves a modest dilution of existing shares, deemed reasonable for the plan’s objectives.
Modalis Therapeutics Corporation announced the issuance of stock options to its employees and subsidiaries to enhance performance and secure skilled human resources. This move is expected to strengthen the company’s operational capabilities and improve its competitive positioning in the biotechnology sector.
Modalis Therapeutics Corporation has outlined its business plans for FY2025, emphasizing its potential for high growth. The announcement highlights the company’s strategic focus on leveraging current market trends and regulatory conditions to enhance its operations and industry positioning, although it acknowledges the inherent risks and uncertainties in forward-looking statements.
Modalis Therapeutics Corporation announced a change in its certified public accountants, with Alpha Audit Corporation set to replace KPMG AZSA LLC after the latter’s term ends on March 27, 2025. This decision, approved by the Audit and Supervisory Committee, aims to bring a fresh audit perspective, appropriate audit fees, and leverage Alpha Audit Corporation’s expertise and quality control, which may impact the company’s financial oversight and stakeholder confidence.
Modalis Therapeutics Corporation announced a proposal to amend its Articles of Incorporation to increase the total number of authorized shares from 100,400,000 to 277,000,000. This strategic move aims to provide the company with more flexibility in capital raising and enhance its capital policy, potentially impacting its growth and market strategy.
Modalis Therapeutics Corporation announced a strategic financial restructuring aimed at improving its financial health by covering a significant deficit in retained earnings. The company’s board has resolved to reduce its stated capital and capital reserves by equal amounts to bolster its capital surplus, which will then be used to offset the deficit, ensuring no impact on share numbers or net asset values.
Modalis Therapeutics Corporation reported a significant reduction in losses for the fiscal year ending December 31, 2024, compared to the previous year. The improvement in financial results is attributed to a decrease in research and development expenses, indicating a shift in the company’s cost management strategies.
Modalis Therapeutics Corporation reported a non-operating income of 64 million yen due to foreign exchange gains for the fiscal year ending December 31, 2024. This financial update highlights the impact of currency fluctuation on the company’s foreign currency denominated assets, potentially affecting their overall financial performance.
Modalis Therapeutics Corporation reported its consolidated financial results for the fiscal year ended December 31, 2024, showing a significant reduction in losses compared to the previous year. Despite the financial improvements, the company has not issued any earnings forecasts for 2025 due to uncertainties in the market.